Multiple Myeloma

1 protocols meet the specified criteria

OCR30423

Phase III Study Of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide Or Lenalidomide As Post-Autologous Stem Cell Transplant Maintenance Therapy In Patients With Multiple Myeloma (MM) Using Minimal Residual Disease To Direct Therapy Duration (DRAMMATIC Study)